A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

NCT05683418 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

241

Enrollment

INDUSTRY

Sponsor class

Conditions

HR+/HER2-negative Breast Cancer

Interventions

DRUG: TOS-358
DRUG: Fulvestrant
DRUG: Palbociclib
DRUG: Ribociclib

Sponsor

Totus Medicines